PFIZER INC
13F Reported Value
ⓘ$170.4M
Holdings
17
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
PFIZER INC disclosed 17 positions worth $170.4M in its Form 13F-HR for Q2 2026, led by $ALLO (Allogene Therapeutics, Inc.) at 27.6% of the equity portfolio, followed by $CELC and $ARVN. During the quarter the fund opened 0 new positions and exited 1 and a full exit from $FIXX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from PFIZER INC’s Form 13F-HR filing with the SEC under CIK 78003.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 33.9#2,371
Quality
$46.9M22,032,040 sh - —
Quality
$29.6M295,652 sh - 36.6#2,264
Quality
$27.7M3,457,815 sh - 16.0
Quality
$19.5M7,032,770 sh - 7.5
Quality
$10.9M1,875,000 sh - —
Quality
$8.0M505,645 sh - 11.7
Quality
$7.9M4,690,431 sh - 57.6
Quality
$5.3M2,362,348 sh - 11.6
Quality
$3.9M953,834 sh - —
Quality
$3.6M372,904 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Allogene Therapeutics, Inc.$ALLO | 33.9#2,371 | $46.9M | 22,032,040 |
 Celcuity Inc.$CELC | — | $29.6M | 295,652 |
 ARVINAS, INC.$ARVN | 36.6#2,264 | $27.7M | 3,457,815 |
 Pyxis Oncology, Inc.$PYXS | 16.0 | $19.5M | 7,032,770 |
 Wave Life Sciences, Inc.$WVE | 7.5 | $10.9M | 1,875,000 |
 Biohaven Ltd.$BHVN | — | $8.0M | 505,645 |
 Caribou Biosciences, Inc.$CRBU | 11.7 | $7.9M | 4,690,431 |
 Spero Therapeutics, Inc.$SPRO | 57.6 | $5.3M | 2,362,348 |
 Zentalis Pharmaceuticals, Inc.$ZNTL | 11.6 | $3.9M | 953,834 |
 Oric Pharmaceuticals, Inc.$ORIC | — | $3.6M | 372,904 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of PFIZER INC's 17 positions.
Showing top 10 of 17 holdings.
Sector Allocation
Healthcare
$170.4M
Technology
$12,418
Full Holdings — PFIZER INC (Q2 2026)
All 17 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ALLO | Allogene Therapeutics, Inc. | $46.9M | 27.6% | +0% | 33.9 |
| 2 | $CELC | Celcuity Inc. | $29.6M | 17.4% | +0% | — |
| 3 | $ARVN | ARVINAS, INC. | $27.7M | 16.2% | +0% | 36.6 |
| 4 | $PYXS | Pyxis Oncology, Inc. | $19.5M | 11.4% | +0% | 16 |
| 5 | $WVE | Wave Life Sciences, Inc. | $10.9M | 6.4% | +0% | 7.5 |
| 6 | $BHVN | Biohaven Ltd. | $8.0M | 4.7% | +0% | — |
| 7 | $CRBU | Caribou Biosciences, Inc. | $7.9M | 4.6% | +0% | 11.7 |
| 8 | $SPRO | Spero Therapeutics, Inc. | $5.3M | 3.1% | +0% | 57.6 |
| 9 | $ZNTL | Zentalis Pharmaceuticals, Inc. | $3.9M | 2.3% | +0% | 11.6 |
| 10 | $ORIC | Oric Pharmaceuticals, Inc. | $3.6M | 2.1% | -92% | — |
| 11 |  $CRDF | Cardiff Oncology, Inc. | $3.0M | 1.8% | +0% | — |
| 12 |  $ZURA | Zura Bio Ltd | $2.9M | 1.7% | -81% | — |
| 13 |  $AGMB | Agomab Therapeutics NV | $1.0M | 0.6% | +0% | — |
| 14 |  $BOLT | Bolt Biotherapeutics, Inc. | $133,832 | 0.1% | +0% | — |
| 15 |  $NXTC | NextCure, Inc. | $72,967 | 0.0% | -71% | — |
| 16 |  $DNA | Ginkgo Bioworks Holdings, Inc. | $30,012 | 0.0% | +0% | 18.8 |
| 17 |  $SENS | Senseonics Holdings, Inc. | $12,418 | 0.0% | +0% | 27.7 |
Exited Positions (1)
$FIXX Q32 Bio Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for PFIZER INC including:
Track PFIZER INC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for PFIZER INC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: PFIZER INC
13F Pro is an AI hedge fund tracker and stock research platform. For PFIZER INC (SEC CIK: 78003), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in PFIZER INC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.